Skip to content

Novartis Scraps Crucial Study as UK Scrambles to Revive Trials

  • Government proposals follow consultation on clinical research
  • UK is seeking to restore its status as a preferred destination
Scientists at a drug laboratory in Oxford, UK.

Scientists at a drug laboratory in Oxford, UK.

Photographer: Adrian Dennis/AFP/Getty Images
Updated on

Novartis AG is scrapping a high-profile UK clinical trial once touted as an example of National Health Service collaboration, even as the government tries to smooth the path for other studies and restore the country’s status as a destination for groundbreaking research. 

The Swiss drugmaker said it has decided not to move forward with Orion-17, a study announced in early 2020 as part of a broader cooperation with the UK government to get a new heart drug to patients.